IP Library Granted Patent US 12,233,136
Granted Patent B2
US 12,233,136 · App. 17/050,741 · Granted Feb 25, 2025

Myosin 15 promoters and uses thereof

Inventors: Joseph Burns (Newton, MA); Kathryn Ellis (Arlington, MA); Adam Palermo (Somerville, MA); Martin Schwander (Auburndale, MA); Jonathon Whitton (Cambridge, MA)
Assignee: Decibel Therapeutics, Inc.
A61K48/0058A61P27/16C07K14/4716C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,136
App. No.
17/050,741
Granted
Feb 25, 2025
Kind
B2
Abstract

The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.

Claims (31)

1. A polynucleotide comprising a first region having at least 85% sequence identity to SEQ ID NO: 1 or a functional portion thereof comprising the sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4, operably linked to a second region having at least 85% sequence identity to SEQ ID NO: 2 or a functional portion thereof comprising the sequence of SEQ ID NO: 8 and/or SEQ ID NO: 9, wherein the first region is fused directly to the second region or is joined to the second region by a linker comprising one to one hundred nucleotides.

2. The polynucleotide of claim 1 , wherein the first region comprises or consists of the sequence of SEQ ID NO: 1.

3. The polynucleotide of claim 1 , wherein the functional portion of SEQ ID NO: 1 comprises the sequence of SEQ ID NO: 3 or the sequence of SEQ ID NO: 4.

4. The polynucleotide of claim 1 , wherein the functional portion of SEQ ID NO: 1 comprises the sequence of SEQ ID NO: 3 and the sequence of SEQ ID NO: 4.

5. The polynucleotide of claim 4 , wherein the functional portion of SEQ ID NO: 1 comprises:

(a) the sequence of SEQ ID NO: 5;

(b) the sequence of SEQ ID NO: 6; or

(c) the sequence of SEQ ID NO: 7.

6. The polynucleotide of claim 1 , wherein the second region comprises or consists of the sequence of SEQ ID NO: 2.

7. The polynucleotide of claim 1 , wherein the functional portion of SEQ ID NO: 2 comprises the sequence of SEQ ID NO: 8 or the sequence of SEQ ID NO: 9.

8. The polynucleotide of claim 1 , wherein the functional portion of SEQ ID NO: 2 comprises the sequence of SEQ ID NO: 8 and the sequence of SEQ ID NO: 9.

9. The polynucleotide of claim 8 , wherein the functional portion of SEQ ID NO: 2 comprises:

(a) the sequence of SEQ ID NO: 10;

(b) the sequence of SEQ ID NO: 11; or

(c) the sequence of SEQ ID NO: 12.

10. The polynucleotide of claim 1 , wherein the polynucleotide comprises or consists of the sequence of SEQ ID NO: 13.

11. A nucleic acid vector comprising the polynucleotide of claim 1 .

12. The nucleic acid vector of claim 11 , wherein the polynucleotide is operably linked to a transgene.

13. The nucleic acid vector of claim 12 , wherein the transgene comprises a nucleic acid sequence encoding a therapeutic protein.

14. The nucleic acid vector of claim 13 , wherein the therapeutic protein is selected from the group consisting of ACTG1, FSCN2, RDX, POU4F3, TRIOBP, TPRN, XIRP2, ATOH1, GFI1, CHRNA9, CIB3, CDH23, PCDH15, KNCN, DFNB59, OTOF, MKRN2OS, LHX3, TMC1, MYO15, MYO7A, MYO6, MYO3A, MYO3B, GRXCR1, PTPRQ, LCE6A, LOXHD1, ART1, ATP2B2, CIB2, CACNA2D4, CABP2, EPS8, EPS8L2, ESPN, ESPNL, PRPH2, STRC, SLC8A2, ZCCHC12, LRTOMT2, LRTOMT1, USH1C, ELFN1, TTC24, DYTN, KCP, CCER2, LRTM2, KCNA10, NT3, CLRN1, CLRN2, SKOR1, TCTEX1D1, FCRLB, SLC17A8, GRXCR2, BDNF, SERPINE3, NHLH1, HSP70, HSP90, ATF6, PERK, IRE1, and BIP.

15. A method of increasing expression of a therapeutic protein in a mammalian hair cell, comprising contacting the mammalian hair cell with the nucleic acid vector of claim 11 .

16. A method of treating a subject having or at risk of developing hearing loss, comprising administering to the subject an effective amount of the nucleic acid vector of claim 11 .

17. A method of treating a subject having or at risk of developing vestibular dysfunction, comprising administering to the subject an effective amount of the nucleic acid vector of claim 11 .

18. A method of promoting hair cell regeneration in a subject in need thereof, comprising administering to the subject an effective amount of the nucleic acid vector of claim 11 .

19. A method of treating a subject having tinnitus, comprising administering to the subject an effective amount of the nucleic acid vector of claim 11 .

20. The polynucleotide of claim 1 , wherein the first region has at least 95% sequence identity to SEQ ID NO: 1 or a functional portion thereof comprising the sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4, and the second region has at least 95% sequence identity to SEQ ID NO: 2 or a functional portion thereof comprising the sequence of SEQ ID NO: 8 and/or SEQ ID NO: 9.

21. The polynucleotide of claim 20 , wherein the first region has the sequence of SEQ ID NO: 1 or a functional portion thereof comprising the sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4, and the second region has the sequence of SEQ ID NO: 2 or a functional portion thereof comprising the sequence of SEQ ID NO: 8 and/or SEQ ID NO: 9.

22. A nucleic acid vector comprising the polynucleotide of claim 10 .

23. The nucleic acid vector of claim 22 , wherein the polynucleotide is operably linked to a transgene.

24. The nucleic acid vector of claim 23 , wherein the transgene comprises a nucleic acid sequence encoding a therapeutic protein.

25. The nucleic acid vector of claim 24 , wherein the therapeutic protein is selected from the group consisting of ACTG1, FSCN2, RDX, POU4F3, TRIOBP, TPRN, XIRP2, ATOH1, GFI1, CHRNA9, CIB3,CDH23, PCDH15, KNCN, DFNB59, OTOF, MKRN2OS, LHX3, TMC1, MYO15, MYO7A, MYO6, MYO3A, MYO3B, GRXCR1, PTPRQ, LCE6A, LOXHD1, ART1, ATP2B2, CIB2, CACNA2D4, CABP2, EPS8, EPS8L2,ESPN, ESPNL, PRPH2, STRC, SLC8A2, ZCCHC12, LRTOMT2, LRTOMT1, USH1C, ELFN1, TTC24,DYTN, KCP, CCER2, LRTM2, KCNA10, NT3, CLRN1, CLRN2, SKOR1, TCTEX1D1, FCRLB, SLC17A8,GRXCR2, BDNF, SERPINE3, NHLH1, HSP70, HSP90, ATF6, PERK, IRE1, and BIP.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2022
From: BURNS, JOSEPH; ELLIS, KATHRYN; PALERMO, ADAM; SCHWANDER, MARTIN; WHITTON, JONATHON
To: DECIBEL THERAPEUTICS, INC.
Reel/Frame 059206/0420 →
Continuity (2)
Provisional Application 62663679 · Apr 27, 2018
Related Publication 20210236654A1 · Aug 5, 2021
References Cited (116)
US 6436392B1 · Engelhardt et al. · 2002 [cited by applicant]
US 6544786B1 · Xiao et al. · 2003 [cited by applicant]
US 6808922B1 · Bebbington et al. · 2004 [cited by applicant]
US 6897045B2 · Engelhardt et al. · 2005 [cited by applicant]
US 7803622B2 · Engelhardt et al. · 2010 [cited by applicant]
US 8236557B2 · Dongsheng et al. · 2012 [cited by applicant]
US 8298818B2 · Boye et al. · 2012 [cited by applicant]
US 11660353B2 · Burns et al. · 2023 [cited by applicant]
US 20030219741A1 · Isogai et al. · 2003 [cited by applicant]
US 20040072154A1 · Morris et al. · 2004 [cited by applicant]
US 20070161031A1 · Trinklein et al. · 2007 [cited by applicant]
US 20080249052A1 · Duan et al. · 2008 [cited by applicant]
US 20100003218A1 · Duan et al. · 2010 [cited by applicant]
US 20100266551A1 · Richard et al. · 2010 [cited by applicant]
US 20120003190A1 · Yamoah et al. · 2012 [cited by applicant]
US 20130210895A1 · Boye et al. · 2013 [cited by applicant]
US 20140256802A1 · Boye et al. · 2014 [cited by applicant]
US 20150065562A1 · Yazicioglu et al. · 2015 [cited by applicant]
US 20150209406A1 · Chen · 2015 [cited by applicant]
US 20160076054A1 · Auricchio et al. · 2016 [cited by applicant]
US 20180055908A1 · Petit et al. · 2018 [cited by applicant]
US 20180327779A1 · Colella et al. · 2018 [cited by applicant]
US 20190002916A1 · Kalatzis et al. · 2019 [cited by applicant]
US 20190153050A1 · Boye et al. · 2019 [cited by applicant]
US 20190185864A1 · Simons et al. · 2019 [cited by applicant]
US 20200155705A1 · Burns et al. · 2020 [cited by applicant]
US 20200157573A1 · Boye et al. · 2020 [cited by applicant]
US 20210388045A1 · Burns et al. · 2021 [cited by applicant]
US 20210395781A1 · Burns et al. · 2021 [cited by applicant]
US 20220064671A1 · Maranga et al. · 2022 [cited by applicant]
US 20240131186A1 · Burns et al. · 2024 [cited by applicant]
US 20240148905A1 · Palermo et al. · 2024 [cited by applicant]
WO WO0125465A1 · 2001 [cited by applicant]
WO WO2009100438A2 · 2009 [cited by applicant]
WO WO2013075008A1 · 2013 [cited by applicant]
WO WO2013158879A1 · 2013 [cited by applicant]
WO WO2014193716A2 · 2014 [cited by applicant]
WO WO2016131981A1 · 2016 [cited by applicant]
WO WO2016139321A1 · 2016 [cited by applicant]
WO WO2017100791A1 · 2017 [cited by applicant]
WO WO2018145111A1 · 2018 [cited by applicant]
WO WO2018204734A1 · 2018 [cited by applicant]
WO WO2019162396A1 · 2019 [cited by applicant]
WO WO2019165292A1 · 2019 [cited by applicant]
WO WO2020093018A1 · 2020 [cited by applicant]
WO WO2020097372A1 · 2020 [cited by applicant]
WO WO2020148458A1 · 2020 [cited by applicant]
WO WO2020163743A1 · 2020 [cited by applicant]
WO WO2021087296A1 · 2021 [cited by applicant]
Caberlotto et al., 2011. Usher type 1G protein sans is a critical component of the tip-link complex, a structure controlling actin polymerization in stereocilia. Proceedings of the National Academy of Sciences, 108(14),… [cited by examiner]
Belyantseva et al., “Myosin XVa localizes to the tips of inner ear sensory cell stereocilia and is essential for staircase formation of the hair bundle,” Proc Natl Acad Sci USA 100(24):13958-63 (2003). [cited by applicant]
Boëda et al., “A specific promoter of the sensory cells of the inner ear defined by transgenesis,” Hum Mol Genet. 10(15): 1581-1589 (2001). [cited by applicant]
Caberlotto et al., “Usher type 1G protein sans is a critical component of the tip-link complex, a structure controlling actin polymerization in stereocilia,” Proc Natl Acad Sci U.S.A. 108(14):5825-30 (2011) (14 pages). [cited by applicant]
GenBank Accession No. JN953192.1, “Mus musculus targeeted KO-first, conditional ready, lacZ-tagged mutant allele Myo15:tm1a(EUCOMM)Wtsi; transgenic,” retrieved from <<https://www.ncbi.nlm.nih.gov/nuccore/JN953192>>, dat… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/029366, dated Sep. 10, 2019 (17 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/017292, mailed Jun. 26, 2020 (18 pages). [cited by applicant]
Schlabach et al., “Synthetic design of strong promoters,” Proc Natl Acad Sci U.S.A. 107(6):2538-43 (2010). [cited by applicant]
Skarnes et al., “Mus musculus targeted non-conditional, lacZ-tagged mutant allele Myo15:tm1e(EUCOMM)Wtsi; transgenic,” GenBank No. JN957158.1, created Nov. 5, 2011, retrieved on Apr. 26, 2020 <https://www.ncbi.nlm.nih.g… [cited by applicant]
Yuhe, Liu, “Preparation of adeno-associated virus vector and its application in cochlea transgenic research,” Chinese Journal of Otology. 4(4):343-347 (2006) (6 pages). [cited by applicant]
Hirsch et al., “Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors,” available in PMC Aug. 3, 2016, published in final edited form as: Methods Mol Biol. 13382:21-39 (2016) (20 pages). [cited by applicant]
Majewski and Ott, “GT Repeats Are Associated with Recombination on Human Chromosome 22,” Genome Res. 10(8): 1108-1144 (Aug. 2000) (7 pages). [cited by applicant]
Lostal et al., “Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors, ” Human Gene Ther. 25(6): 552-562 (Jun. 2014) (11 pages). [cited by applicant]
Gao et al., “The Dystrophin Complex: structure, function and implications for therapy,” available in PMC Jul. 1, 2016, published in final edited form as: Compr Physiol. 5(3): 1223-1239 (Jul. 2015) (33 pages). [cited by applicant]
Dyka et al., “Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A,” Human Gene Ther Methods. 25(2): 166-77 (Apr. 2014) (12 pages). [cited by applicant]
Pryadkina et al., “A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence,” Mol Ther Methods Clin Dev. 2: 15009 (Mar. 2015) (12 pages). [cited by applicant]
Geleoc et al., “Sound strategies for hearing restoration,” available in PMC Aug. 29, 2014, published in final edited form as: Science. 344(6184):1241062 (May 2014) (20 pages). [cited by applicant]
Corns et al., “Mechanotransduction is required for establishing and maintaining mature inner hair cells and regulating efferent innervation,” Nat Commun. 9(1):4015 (Oct. 2018) (15 pages). [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/017058, dated Jun. 14, 2022 (14 pages). [cited by applicant]
Yoshimura et al., “Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation,” Scientific Reports. 8:2980 (with supplemental material) (Feb. 2018… [cited by applicant]
Pangrsic et al., “Otoferlin: a multi-C [cited by applicant]
Holt et al., “Split otoferlin reunited,” EMBO Molecular Medicine. 11:(1)e9995 (Jan. 2019) (3 pages). [cited by applicant]
Suzuki et al., “Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction,” Scientific Reports. 7(1):45524 (Apr. 2017) (11 pages). [cited by applicant]
Tertrais et al., “Viral Transfer of Mini-Otoferlins Partially Restores the Fast Component of Exocytosis and Uncovers Ultrafast Endocytosis in Auditory Hair Cells of Otoferlin Knock-Out Mice,” J. Neurosci. 39(18):3394-34… [cited by applicant]
Petrs-Silva et al., “Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse Retina,” Molecular Therapy. 19(2):293-301 (Feb. 2011) (9 pages). [cited by applicant]
American Academy of Audiology, “Children's Hospital of Philadelphia Performs First Gene Therapy Procedure to Treat Genetic Hearing Loss in United States,” <https://www.audiology.org/childrens-hospital-of-philadelphia-pe… [cited by applicant]
Yoshimura et al., “Targeted Allele Suppression Prevents Progressive Hearing Loss in the Mature Murine Model of Human TMC1 Deafness,” Molecular Therapy. 27(3):681-690 (with supplemental material) (Mar. 2019) (17 pages). [cited by applicant]
Akil et al., “Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane,” Journal of Visualized Experiments. 97(1):e52187 (Mar. 2015) (7 pages). [cited by applicant]
Liu et al., “Specific and Efficient Transduction of Cochlear Inner Hair Cells with Recombinant Adeno-associated Virus Type 3 Vector,” Molecular Therapy. 12(4):725-733 (Oct. 2005) (9 pages). [cited by applicant]
“Basics of sound, the Ear, and Hearing,” [cited by applicant]
Akil et al., “AAV-Mediated Gene Delivery to the Inner Ear,” [cited by applicant]
Langouet-Astrie et al., “Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells,” Experimental Eye Research. 151(1):61-67 (Jul. 20… [cited by applicant]
Li et al., “A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization,” J. Cell. Mol. Med. 21(8):1555-1571 (Aug. 2017) (17 pages). [cited by applicant]
Lopes-Pacheco et al., “Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells,” Experimental Cell Research. 372:99-107 (Sep. 2018) (9 pages). [cited by applicant]
Petrs-Silva et al., “High-efficiency Transduction of the Mouse Retina by Tyrosine-mutant AAV Serotype Vectors,” Molecular Therapy. 17(3):463-471 (Mar. 2009) (9 pages). [cited by applicant]
Kilpatrick et al., “Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear,” Gene Therapy. 18(6):569-578 (Jan. 2011) (10 pages). [cited by applicant]
Tao et al., “Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction,” Human Gene Therapy. 29(4):492-506 (Nov. 2017) (15 pages). [cited by applicant]
Zhang et al., “Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success,” Front. Mol. Neurosci. 11(221): 1-15 (Jun. 2018) (15 pages). [cited by applicant]
Roux et al., “Otoferlin, Defective in a Human Deafness Form, Is Essential for Exocytosis at the Auditory Ribbon Synapse,” Cell. 127(2):277-289 (Oct. 2006) (13 pages). [cited by applicant]
“Genetic Hearing Loss With No Associated Abnormalities,” [cited by applicant]
Ahmed et al., “Emerging Gene Therapies for Genetic Hearing Loss,” JARO. 18(5):649-670 (Aug. 2017) (22 pages). [cited by applicant]
Zhang et al., “Temperature sensitive auditory neuropathy,” Hearing Research. 335(1):53-63 (Jan. 2016) (11 pages). [cited by applicant]
Hamosh et al. “OTOFERLIN; OTOF,” OMIM. (Apr. 2015) (8 pages) retrieved via The Wayback Machine on Jul. 29, 2015, URL: <https://web.archive.org/web/20150729163826/http://omim.org/entry/603681>. [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/016218, mailed Jul. 12, 2024 (19 pages). [cited by applicant]
Kim et al., “Direct isolation and identification of promoters in the human genome,” Genome Res. 15(6):830-9 (Jun. 2005) (11 pages). [cited by applicant]
Akil et al., “Dual AAV gene therapy restores hearing in a mouse model for human genetic Deafness,” International Symposium on Inner Ear Therapies (ISIET), Marrakech, Morocco. 21 (2017) (Abstract only). [cited by applicant]
Akil et al., “Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model,” Proc Natl Acad Sci U S A. 116(10):4496-4501 (2019). [cited by applicant]
Al-Moyed et al., “A dual AAV viral vector approach partially restores exocytosis and rescues hearing in deaf otoferlin knock-out mice,” ARO Abstracts. 41:76 (2018) (Abstract only). [cited by applicant]
Al-Moyed et al., “A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice,” EMBO Molecular Medicine. 11(1):e9396 (2019) (13 pages). [cited by applicant]
Alemi, “Progress Report: AOS Research Grant: Restoration of Hearing in the Otoferlin Knockout Mouse using Viral Gene Therapy,” 145th Annual Meeting of the American Otological Society, Inc, Apr. 21-22, San Diego, Califor… [cited by applicant]
Choi et al., “Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in Pakistan,” available in PMC Oct. 1, 2012, published in final edited form as: Clin Genet. 75(3):237-243 (2009) … [cited by applicant]
Duan et al., “Expanding AAV Packaging Capacity with Trans-splicing or Overlapping Vectors: A Quantitative Comparison,” Mol Ther. 4(4):383-91 (2001). [cited by applicant]
Mcclements et al., “Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes,” Yale J Biol Med. 90(4):611-623 (2017). [cited by applicant]
Trapani et al., “Effective delivery of large genes to the retina by dual AAV vectors,” EMBO Mol Med. 6(2):194-211 (2014). [cited by applicant]
Trapani et al., “Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease,” Hum Mol Genet. 24(23):6811-25 (2015). [cited by applicant]
Yasunaga et al., “OTOF Encodes Multiple Long and Short Isoforms: Genetic Evidence That the Long Ones Underlie Recessive Deafness DFNB9,” Am J Hum Genet. 67(3):591-600 (2000). [cited by applicant]
Xu et al., “Trans-Splicing Adeno-Associated Viral Vector-Mediated Gene Therapy Is Limited by the Accumulation of Spliced mRNA but Not by Dual Vector Coinfection Efficiency,” available in PMC Jun. 19, 2008, published in … [cited by applicant]
Ghosh et al., “A Hybrid Vector System Expands Adeno-associated Viral Vector Packaging Capacity in a Transgene-independent Manner,” The American Society of Gene Therapy. 16(1):124-130 (2008). [cited by applicant]
Ghosh et al., “Efficient Transgene Reconstitution with Hybrid Dual AAV Vectors Carrying the Minimized Bridging Sequences,” Hum Gene Ther. 22(1):77-83 (2011). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/017257, dated Apr. 29, 2020 (22 pages). [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2020/058265, mailed Feb. 8, 2021 (15 pages). [cited by applicant]
Michalski et al., “Genetics of auditory mechano-electrical transduction,” Pflugers Arch. 467(1):49-72 (2015). [cited by applicant]
Skarnes et al., “A conditional knockout resource for the genome-wide study of mouse gene function,” available in PMC Feb. 14, 2013, published in final edited form as: Nature. 474(7351):337-342 (2011) (18 pages). [cited by applicant]
Boye et al., “Transduction and Tropism of an Abbreviated Form of CMV-Chicken β-Actin Promoter (CBA) With AAV in Mouse Retina,” ARVO Annual Meeting Abstract May 2006, published in: Investigative Ophthalmology & Visual Sc… [cited by applicant]
Lovell, “Mouse DNA sequence from clone RP23-135F6 on chromosome 11,” European Nucleotide Archive, EMBL-EBI. (2012) (15 pages). [cited by applicant]
Wang, Aihui, Dissertation: “Molecular Cloning of an Unconventional Myosin MYO15 and the Identification of Mutations of MYO15 Responsible for Human Nonsyndromic Deafness DFNB3,” Doctor of Philosophy, Graduate Program in … [cited by applicant]
Liang et al., “Characterization of the Human and Mouse Unconventional Myosin XV Genes Responsible for Hereditary Deafness DFNB3 and Shaker 2,” Genomics. 61(3):243-258 (1999). [cited by applicant]
Cited By (2)
US 12,410,442 US 12,589,168